Flavone-8-acetic acid (FAA) is a synthetic flavonoid with impressive preclinical activity but no clinical activity as a single agent (Kerr & Kaye, 1989) . 5,6-MeXAA is a fused tricyclic analogue of FAA developed in this laboratory (Rewcastle et al., 1991) . It has improved antitumour activity and 12-fold higher dose potency when compared to FAA, and is a candidate drug for clinical trial. FAA and 5,6-MeXAA share many properties with endotoxin: they induce the synthesis of tumour necrosis factor (TNF) (North & Havell, 1988; Mace et al., 1990) and stimulate the formation of nitric oxide, both in vitro (Drapier et al., 1988; Thomsen et al., 1990) and in vivo (Stuehr & Marletta, 1985; Thomsen et al., 1991) . There are two main facets to the action of these agents. Firstly, by inducing TNF they promote the cessation of tumour blood flow and cell death by tumour ischaemia (Evelhoch et al., 1988; North & Havell, 1988; Zwi et al., 1989; Mahadevan et al., 1990) . Secondly, macrophage- (Stewart et al., 1988) or lymphocyte (Berendt et al., 1978) mediated cytotoxicity leads to further killing of residual tumour cells. T-lymphocyte mediated immunity has been implicated in the action of both endotoxin (Berendt et al., 1978) and of FAA (Pratesi et al., 1990; Bibby et al., 1991) . We report here that FAA and 5,6-MeXAA induce growth delays and cures of the Colon 38 adenocarcinoma in T-cell depleted mice, and can therefore function effectively, at least against some tumours, by T-cell independent mechanisms.
As demonstrated previously (Rewcastle et al., 1991; Thomsen et al., 1991) injected intravenously and mice were used for experiments 6 weeks after bone marrow reconstitution. At the end of each experiment, all mice were examined for complete removal of thymic glands. T-cell deficiency was checked by culturing spleen cells (106 cellsml-') from individual mice with concanavalin A (2pgml-'; Sigma) and measuring tritiated thymidine uptake after 3 days. T x B mice incorporated less than 5% of the radioactivity of that of euthymic controls.
Colon 38 fragments were implanted subcutaneously. Mice bearing tumours 4-8 mm in diameter were selected for each experiment and randomised with respect to tumour size into treatment and control groups (at least five mice per group). FAA (obtained from the National Cancer Institute, USA) and the sodium salt of 5,6-MeXAA (synthesised in this laboratory) were dissolved in 5% (w/v) sodium bicarbonate, protected from light (Rewcastle et al., 1990) (Table I) . Drug toxicity, when present, occurred within 24 h of administration and was more frequent in T x B mice than in nude or euthymic mice. 5,6-MeXAA and FAA induced growth delays in all three groups of mice, although tumour cure rates for 5,6-MeXAA in T x B and athymic mice were lower than in euthymic mice (Table I) . Mean tumour volumes in both FAA and 5,6-MeXAA treated groups were significantly lower from day 4 after treatment in T x B mice ( Figure 1 ) and from day 3 after treatment in athymic mice (Figure 2 ). Within the limits imposed by the numbers of animals used, there was no relationship between initial tumour size and either toxicity or cure rate.
To evaluate the role of tumour haemorrhagic necrosis in tumour response, some tumours were removed 24 h after drug treatment, fixed, embedded, sectioned and stained with haematoxylin and eosin. A grid marked at 0.4 mm intervals was placed over the slide and the intersections were scored as either undamaged or necrotic as previously described . The results were similar for all three groups of mice and confirmed the conclusion, obtained previously with FAA and other analogues (Thomsen et al., 1991) , that aData averaged from several experiments (Rewcastle et al., 1991; Thomsen et al., 1991) . and tumour volumes (pi) were compared with those in naive euthymic control mice (five mice; 0). tumour necrosis was necessary but not sufficient for significant tumour growth delay. To determine whether immunity had been generated by the growth of the primary tumour, mice which had previously been cured by treatment with either FAA or 5,6-MeXAA were reimplanted after 140 days with a second Colon 38 tumour. Secondary implants were found to grow in T x B mice at the same rates at in naive euthymic control mice (Figure 3 ). Secondary Colon 38 implants also grew in previously cured euthymic hosts. Although a slightly longer time was required for tumours to become palpable, the tumour volumes were not significantly smaller than those in the control mice (Figure 3 ). Lewis lung tumours (Finlay et al., 1988) were found to grow equally well in naive control mice or euthymic or T x B mice which had previously been cured of a Colon 38 tumour (data not shown).
The results (Table I ) contrast with those of other reports (Pratesi et al., 1990; Bibby et al., 1991) where inhibition of tumour growth by FAA was observed in euthymic hosts only, but emphasise the heterogeneity of host antitumour response mechanisms. Although differing drug administration schedules may have played a role, the most likely explanation for this discordance is that T-cell dependent cytotoxicity is less important in the response of Colon 38 tumours than it is in the other tumours reported. North and co-workers have shown that different murine tumour models vary in their immunogenicity and in their effects on the host's immunity (Berendt et al., 1978) . Immunogenic tumours induce the generation of long-term T-cell immunity specific to the tumour, while others induced suppression of initially generated immunity, and yet are non-immunogenic with no effect on the immunity of the host. The longer lag period required before a second Colon 38 implant became palpable in previously cured mice, together with the observation that there were more complete regressions of the primary tumours in euthymic hosts than in T-cell deficient mice, suggest that Colon 38 may be weakly immunogenic.
In summary, we have demonstrated haemorrhagic necrosis, growth delay and complete regression of Colon 38 tumours which appear to be largely independent of T-cell activity. Other mechanisms of potential cytotoxicity, including the induction of cells in the natural killer lineage (Hornung et al., 1988) , and macrophage-mediated killing via the production of TNF or nitric oxide (Ching & Baguley, 1988; Thomsen et al., 1990) , may thus operate in concert with tumour ischaemia (Zwi et al., 1989) to cause tumour regression, with the contributions of each varying according to the tumour.
